NXG Swiss Excellence

NAV: CHF 108.39

I: CH0382<u>913793</u>

Performance graph 125

115



Investment objective

The NXG Swiss Excellence Strategy focuses on shares of Swiss companies that reflect "Swiss Excellence" worldwide as well as Swiss companies that are or are expected to become Swiss leaders. The portfolio will be rebalanced according to the global views of NextGen Wealth Managers' investment committees and daily meetings between analysts and portfolio managers.

Key features

Concentrated portfolio of around 30 companies

· Swiss Excellence played through three thematics

· Actively managed portfolio


AMC data			
Quote	108.39		
Share class currency	CHF		
AUM (CHF Mn)	10.0		
Advisor	NextGen Wealth Managers SA		
Calculation Agent	Bank Vontobel AG, Zurich		
ISIN	CH0382913793		
Valor	50670284		
Benchmark	Swiss Leader Index (SLI)		
Issue date	31.08.2021		
Management fees	0.65%		
Administration fees	0.30%		
Performance fees	-		
Quotation	Daily		
Subscription/redemption	Daily/daily		
Minimum investment	1 Certificate		
Registration	Switzerland		
Domicile	Switzerland		
Dividend distribution	Capitalized		

Monthly comment

In February, Swiss equities continued to appreciate but lagged once again the other major indices, both in CHF and local currencies terms. The SMI rose 0.9%, against 8.1% for the S&P 500 and 5.6% for the Eurostoxx 50, in CHF terms. Swiss mid-caps were the driver of the performance of the portfolio this month, while small-cap stalled during the month. The CHF depreciated against major currencies on inflation data showing no sign of rebounding and the data on foreign exchange holdings suggests the SNB might have intervened against an appreciation of the CHF.

The portfolio rose 2.4% versus 3.1% for the SLI in February. The monthly underperformance came from our selection of information and technology stocks. However, our selection of financials contributed positively. Top monthly contributors were Richemont (+9.0%), ABB (+11.0%) and Sulzer (+23.5%). On the flip side, Nestlé (-6.9%), Roche (-6.1%) and Also (-8.7%) were the main detractors. We initiated a position on UBS (1.5%) in February, as the outlook after the purchase of Credit Suisse became clearer, and exited Temenos after the suspicions of books manipulation came out. Our position before the news came out was relatively small at 2.3%. We increased our positions in SGS and Sika and reduced Zurich as its weigh in the portfolio grew significantly bigger after a strong performance in the last months.

The earnings season for the 2023 financial year is in full swing and most Swiss companies have already reported. The reports have been mitigated. As the SNB starts to ease its monetary policy and limit the CHF appreciation, it should bolster the Swiss exporters.



Market capitalization Large 82% Mid 4% Small 8% Top ten concentration Top ten 49% Rest 51%	Excellence thematics	World Champions 68%		Born Specialists 16%Tomorrow's Winners 10%	
Top ten concentration Top ten 49% Rest 51%	Market capitalization	Large 82%	Mid 4%		Small 8%
	Top ten concentration	Top ten 49%		Rest 51%	

Allocation